COMP <GO>
XGN vs ABBV // OPERATING MARGIN
Exagen Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: XGN 1
— ABBV 10
▲ OPERATING MARGIN LEADER: ABBV
LAST: $8.70 (+3.57%) • MKT CAP: $210.8M
operating-margins
-21.10%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
operating-margins
24.60%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XGN VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XGN | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 58.30% | 70.20% | -11.90 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 29.00% | -64.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.77% | 3.47% | -10.24 | ABBV | /fcf-yield <GO> |
| Operating Margin ACTIVE | -21.10% | 24.60% | -45.70 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -30.00% | 6.90% | -36.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 19.70% | 8.60% | +11.10 | XGN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.33 | -5.13 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.6 | 65.1 | -6.48 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $210.8M | $513.86B | -$513.65B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XGN REV | ABBV REV | XGN GROSS % | ABBV GROSS % | XGN FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $66.6M | $61.16B | 58.3% | 70.2% | -$14.3M | $17.82B |
| FY 2024 | $55.6M | $56.33B | 59.5% | 70.0% | -$13.8M | $17.83B |
| FY 2023 | $52.5M | $54.32B | — | — | -$14.5M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XGN // BETA —
ABBV // BETA 1.15